tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Oct 21;10(10):1765.
doi: 10.3390/vaccines10101765.
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand
Saraiorn Thonginnetra[SUP] 1 [/SUP], Kriangkrai Tawinprai[SUP] 2 [/SUP], Krongkwan Niemsorn[SUP] 1 [/SUP], Pathariya Promsena[SUP] 1 [/SUP], Manunya Tandhansakul[SUP] 1 [/SUP], Naruporn Kasemlawan[SUP] 1 [/SUP], Natthanan Ruangkijpaisal[SUP] 1 [/SUP], Narin Banomyong[SUP] 1 [/SUP], Nanthida Phattraprayoon[SUP] 3 [/SUP], Pisuttikan Rangkakulnuwat[SUP] 1 [/SUP], Preeda Vanichsetakul[SUP] 1 [/SUP], Teerapat Ungtrakul[SUP] 3 [/SUP], Kasiruck Wittayasak[SUP] 4 [/SUP], Nawarat Thonwirak[SUP] 4 [/SUP], Kamonwan Soonklang[SUP] 4 [/SUP], Nithi Mahanonda[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10-17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21-28 days apart. To assess vaccine safety, 36,808 participants were then followed with paper- and web-based online questionnaire surveys that captured local and systemic reactogenicities following vaccine administration on days 1, 7, and 30. Among participants, 76% (27,880) reported reactogenicity within the first 24 h and 7 days following the first dose. Half (51.41%) of participants experienced pain at the injection site; the majority of cases were mild in severity. Injection site tenderness (37.93%) was another common local reaction. Fatigue (37.89%), myalgia (33.56%), and headache (26.76%) were the most common systemic reactions. On days 2-7 after the first dose, 25.85% of participants experienced adverse reactions. Following the second dose, reactogenicity was 7.6% and 1.09% within 24 h and between days 2-7. The majority of reactions were of mild to moderate severity. We report that two doses of the BBIBP-CorV caused mild to moderate side effects in adolescents in Thailand. The findings confirm the vaccine's safety profile in this age group.
Keywords: BBIBP-CorV; COVID-19; SARS-CoV-2; adolescent; children; immunization; safety; vaccination.
. 2022 Oct 21;10(10):1765.
doi: 10.3390/vaccines10101765.
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand
Saraiorn Thonginnetra[SUP] 1 [/SUP], Kriangkrai Tawinprai[SUP] 2 [/SUP], Krongkwan Niemsorn[SUP] 1 [/SUP], Pathariya Promsena[SUP] 1 [/SUP], Manunya Tandhansakul[SUP] 1 [/SUP], Naruporn Kasemlawan[SUP] 1 [/SUP], Natthanan Ruangkijpaisal[SUP] 1 [/SUP], Narin Banomyong[SUP] 1 [/SUP], Nanthida Phattraprayoon[SUP] 3 [/SUP], Pisuttikan Rangkakulnuwat[SUP] 1 [/SUP], Preeda Vanichsetakul[SUP] 1 [/SUP], Teerapat Ungtrakul[SUP] 3 [/SUP], Kasiruck Wittayasak[SUP] 4 [/SUP], Nawarat Thonwirak[SUP] 4 [/SUP], Kamonwan Soonklang[SUP] 4 [/SUP], Nithi Mahanonda[SUP] 2 [/SUP]
Affiliations
- PMID: 36298630
- DOI: 10.3390/vaccines10101765
Abstract
Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10-17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21-28 days apart. To assess vaccine safety, 36,808 participants were then followed with paper- and web-based online questionnaire surveys that captured local and systemic reactogenicities following vaccine administration on days 1, 7, and 30. Among participants, 76% (27,880) reported reactogenicity within the first 24 h and 7 days following the first dose. Half (51.41%) of participants experienced pain at the injection site; the majority of cases were mild in severity. Injection site tenderness (37.93%) was another common local reaction. Fatigue (37.89%), myalgia (33.56%), and headache (26.76%) were the most common systemic reactions. On days 2-7 after the first dose, 25.85% of participants experienced adverse reactions. Following the second dose, reactogenicity was 7.6% and 1.09% within 24 h and between days 2-7. The majority of reactions were of mild to moderate severity. We report that two doses of the BBIBP-CorV caused mild to moderate side effects in adolescents in Thailand. The findings confirm the vaccine's safety profile in this age group.
Keywords: BBIBP-CorV; COVID-19; SARS-CoV-2; adolescent; children; immunization; safety; vaccination.